Rationale for angiotensin II receptor blocker therapy in chronic heart failure

Jay N. Cohn

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Inhibiting the synthesis of angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) inhibitor treatment has long been established as the recommended therapy for heart failure (HF). As ACE inhibitors are only partially effective in blocking the formation of Ang II, additional treatment with selective Ang II receptor blockers (ARBs) promise additional benefits in patients with HF. This hypothesis is currently being evaluated in Val-HeFT, a large-scale, randomised, double-blind, placebo-controlled study on the effects of adding the highly selective ARB valsartan to usual therapy (diuretics, digoxin, beta-blockers, ACE inhibitors) for HF treatment.

Original languageEnglish (US)
Pages (from-to)38-40
Number of pages3
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Issue numberSUPPL. 2
StatePublished - Dec 2000


  • Angiotensin II
  • Angiotensin II receptor blockade
  • Combination treatment
  • Congestive heart failure
  • Mortality study


Dive into the research topics of 'Rationale for angiotensin II receptor blocker therapy in chronic heart failure'. Together they form a unique fingerprint.

Cite this